Kari Tikkinen: Defining Thromboprophylaxis in MIBC Neoadjuvant Care
Kari Tikkinen, Professor of Public Health at University of Helsinki, shared a post on LinkedIn, about recent article by Alex L.E. Halme et al. published in Clinical-Genitourinary, adding:
“Hot off the press – ACB Survey published in Clinical Genitourinary Cancer This marks the first publication from our new ACB research programme, focused on generating evidence to guide anticoagulation decisions during neoadjuvant treatment for muscle-invasive bladder cancer (MIBC).
Should patients with MIBC receive thromboprophylaxis during neoadjuvant therapy?
Shortly: We urgently need better evidence.
Our international survey on thromboprophylaxis practices during neoadjuvant chemotherapy (NAC) for MIBC is published:
Why this matters
- MIBC patients receiving NAC have meaningful risk of thrombosis
- VTE before cystectomy may delay surgery and cause serious complications
- Anticoagulation may reduce VTE but can increase bleeding
- Guidelines remain unclear
What did we do?
- International survey in United Kingdom, Finland, Sweden, Denmark and Iceland.
- Clinicians treating MIBC with NAC
- High response rate (69%) and very high completion rate (98%)
Findings
- 57% prescribed no thromboprophylaxis during NAC (and 43% did)
- 72% prescribed prophylaxis to fewer than 10% of patients and only 4% prescribed it to ≥90% of patients
- LMWH preferred agent when used, followed by DOACs
- Main reasons for withholding: insufficient evidence of benefit (57%), bleeding concerns (28%)
- 72% interested in joining a randomized trial
Interpretation and Implications
- Practice heterogeneous
- Concerns about both thrombosis and bleeding
- A definitive randomized trial is needed
- Future work should identify who benefits most, and who may be harmed
This survey directly supports the rationale for the ACB research programme:
Trial on apixaban vs no anticoagulation during neoadjuvant for MIBC
Net clinical benefit: preventing thrombosis without causing unacceptable bleeding
Toward precision thromboprophylaxis: identifying who benefits, who is harmed, and who can safely avoid anticoagulation
Big thanks to all participating clinicians and collaborators across the UK and Nordic countries!
Big thanks to all co-authors.”
Title: International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer
Authors: Alex L.E. Halme, Matias Posa, Jani Ruotsalainen, Sanna Hallamies, Andreas Carus, Sigurdur Gudjonsson, Heikki Junkkari, Riikka Järvinen, Niko K. Nordlund, Sara Tornberg, Anders Ullén, Peter L. Gross, Kirsi-Maija Kaukonen, James W.F. Catto, Syed A. Hussain, Kari A.O. Tikkinen
Stay updated on all scientific advances with Hemostasis Today.
-
May 13, 2026, 16:41Seema Dawood: When Elevated Platelets Signal a Myeloproliferative Neoplasm
-
May 13, 2026, 16:28Nadia Tarhini: Evaluating the Risk of Recurrent Thrombosis in Children with ALL
-
May 13, 2026, 16:01Sifat Jubaira: When Low MCV Meets High Platelets
-
May 13, 2026, 15:58Aktham El-rekaby: Immunothrombosis in Acute Ischaemic Stroke
-
May 13, 2026, 15:49Alison Dougall: Oral Health and Cardiovascular Risk in Bleeding Disorders
-
May 13, 2026, 15:38International Journal of Stroke: Oral Anticoagulants and DOAC–Antiplatelet Therapy Are Associated with Increased Major Bleeding Risk
-
May 13, 2026, 15:19Papa Heme։ Causes of Isolated Prolonged aPTT Without Bleeding
-
May 13, 2026, 15:10Wolfgang Miesbach: Rethinking Bleeding Risk in Anticoagulation
-
May 13, 2026, 15:09Veronica Sanchez: Better Cardiovascular Health Helps Lower Heart Attack Risk